Friday, July 10, 2026

pharma · Critical Limb Ischemia (CLI) · Sarcoma · DSGN

Lxo Ireland Designated

Lxo Ireland Designated is a pharma organization headquartered in CARLSBAD, CA, IE. It trades on NYSE under ticker DSGN. Primary therapeutic focus areas include Critical Limb Ischemia (CLI), Sarcoma, Friedreich Ataxia, HP

CARLSBAD, CA, IE HQ
Public company Type
DSGN · NYSE Ticker
Company details
Clinical program

Autologous Bone Marrow Mononuclear Cells

Phase 2 · other · Peripheral Vascular Diseases

Autologous Bone Marrow Mononuclear Cells for Peripheral Vascular Diseases is a Phase 2 program (other) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).

Internal code C/ICPD/2007

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Lxo Ireland Designated Activity Company
Phase
Phase 2
Modality
other
Indication
Peripheral Vascular Diseases
Status
completed
Trials
1